Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Company Overview

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials. These programs explore combinations of targeted therapy and standard chemotherapy in colorectal, ovarian and breast cancers. Allarity’s diagnostic platform supports these efforts by employing gene expression signatures to match treatments with tumor biology, offering a more personalized approach than conventional “one‐size‐fits‐all” regimens.

Founded in 2015 as OncoBay, the company rebranded to Allarity Therapeutics in 2020 to reflect its expanded precision medicine strategy. Headquartered in Copenhagen, Denmark, Allarity maintains a U.S. presence in Cambridge, Massachusetts, to facilitate clinical collaborations and regulatory interactions. Under the leadership of CEO Christian M. Vedelsdal and an experienced executive team, the company has built partnerships with research institutions and contract organizations to advance its clinical programs.

Allarity serves global markets by enrolling patients across North America and Europe in its ongoing trials. The company’s outward focus on combining diagnostics with therapeutics aligns with an evolving industry trend toward more targeted and data‐driven drug development, positioning Allarity to address significant unmet needs in oncology with a precision‐guided approach.

Key Stats

• Today's Range: $1.56 to $1.72
• 50-Day Range: $1.04 to $1.77
• 52-Week Range: $0.77 to $2.35
• Volume: 156,951 shs
• Average Volume: 257,875 shs
• Market Capitalization: $25.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.75
• Consensus Rating: Hold

Allarity Therapeutics Stock Analysis - MarketRank™

Allarity Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 711th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Allarity Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Allarity Therapeutics has a consensus price target of $9.75, representing about 505.6% upside from its current price of $1.61.

Amount of Analyst Coverage

Allarity Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Allarity Therapeutics are expected to decrease in the coming year, from ($0.96) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allarity Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allarity Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allarity Therapeutics has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.87% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 1.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently increased by 8.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allarity Therapeutics does not currently pay a dividend.

Dividend Growth

Allarity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Allarity Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Allarity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for ALLR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.08% of the stock of Allarity Therapeutics is held by insiders.

Percentage Held by Institutions

11.53% of the stock of Allarity Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/05/2026
• Next Earnings (Estimated): 8/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALLR
• CIK: 1860657
• Web: www.allarity.com
• Phone: 401-426-4664
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Allarity Therapeutics: $9.75
• High Price Target: $9.75
• Low Price Target: $9.75
• Potential Upside/Downside: +505.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.23 million
• Net Margins: N/A
• Pretax Margin: -3,260.58%
• Return on Equity: -109.94%
• Return on Assets: -47.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $320 thousand
• Price / Sales: 80.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 2.64

Miscellaneous

• Outstanding Shares: 15,910,000
• Free Float: 15,898,000
• Market Cap: $25.62 million
• Optionable: Not Optionable
• Beta: 0.52